Oct
26

The ONLY Peer-Reviewed Journal for Medical Science Liaisons Is Now Available

The Medical Science Liaison Society has officially launched the industry’s first, peer-reviewed journal specifically targeting the professional Medical Science Liaison (MSL).

THE MSL: Journal of the Medical Science Liaison Society is the industry’s premier peer-reviewed publication for the MSL profession.

The journal was created to provide insights and knowledge exchange among the Medical Science Liaison community. The Journal is a multidisciplinary, international journal and invites submissions from authors in all relevant disciplines and settings.

The journal will publish six issues a year and is available in both digital and printed versions. We provided a complimentary print copy of the first issue to all attendees at our recent annual U.S. MSL Society conference. The digital version officially launched today. All members of the MSL Society receive a free digital subscription.

We are very excited to bring this resource to the global MSL community!

Thanks to all the authors that contributed great articles to our first issue:

Dr. Hudson Garrett

Vice President, Clinical Affairs and Medical Affairs

PDI Inc.

Dr. Alexander Tolmachev

Senior Manager, Medical and Regulatory Projects

Takeda, Russia

Dr. Jennifer Williams

Director of TTM Education and MSL Services

Bard Medical

Dr. Eric Zhao

Regional Medical Liaison, Oncology

Amgen Inc.

Thanks also to our first advertisers for their support as well:

Thought Leader Select

Veeva Systems

BestMSLs

The second issue will be published next month. To read the first issue or learn about subscriptions see themsljournal.com

Want to get involved or publish?

To submit an article for consideration, please visit www.themsljournal.com and submit the manuscript through the online portal for peer review and consideration by the Editor. The Journal is also looking for peer reviewers, so if you are interested in applying as a reviewer, please email Dr. Hudson Garrett, Editor-In-Chief at hudson.garrett@themsls.org.

Jul
10

Medical Science Liaison Job Satisfaction & Best Company to Work For

 

Best Company To Work ForThe Medical Science Liaison Society is conducting the first MSL Job Satisfaction & Best Company to Work For Survey. We are conducting this to gain insights into current MSL Job Satisfaction and identify the BEST companies to work for according to current MSLs across pharmaceutical, biotechnology, medical devices and other healthcare companies. We will be creating a full report of the results, which we will publish in the fall of 2015.

 

 

This Survey is ONLY open to current MSLs (or equivalent title) and MSL management!

Take the survey: http://www.surveygizmo.com/s3/2213982/MSLJobSatisfaction

 

Questions you may have:

Why Should I Participate in This Survey?

Participants who complete the survey will help build an understanding of MSL job satisfaction based on numerous important factors. We will share the results with the global MSL community. 

Will I Receive the Results of This Survey?

Yes, if you provide your name and e-mail address at the end of the survey, we will e-mail you the results of the survey when the report is published in the fall of 2015. 

Are My Responses Kept Confidential?

Yes, your survey responses will be kept strictly confidential; all data is blinded and aggregated to maintain confidentiality.

Will the MSL Society Share the Results?

Yes, everyone who participates and shares their contact details as well as all members of the MSL Society will receive the full report. In addition, ALL attendees at the upcoming annual MSL Society Conference being hosted by Genzyme in Boston, September 29-October 1st will receive a copy as well.

This survey should take less than 10 minutes to complete. All questions are required.

On behalf of the MSL Society, we thank you in advance for your participation and look forward to sharing the results soon!

Take the survey now: http://www.surveygizmo.com/s3/2213982/MSLJobSatisfaction

 

About the MSL Society: 

The Medical Science Liaison Society is a 501c3 nonprofit organization and is the ONLY organization exclusively dedicated to the global MSL profession. The society helps MSLs become more effective in their careers through education and networking activities. The organization provides resources for professional growth and development opportunities by creating original research reports, hosting the only career center for MSLs, and providing digital and live MSL training programs, which have been conducted in multiple countries. In addition, the MSL Society has consulted with numerous companies on successfully launching MSL teams, ongoing MSL training, and effective MSL-KOL engagement, among other projects.

Jul
16

New MSL Society White Paper: Implications of the Sunshine Act on Medical Science Liaisons and their Companies

Earlier this year, the MSL Society had the privilege of collaborating with the Rutgers University Pharmaceutical Industry Fellowship Program on a new study centering on the recently enacted Physician Payments Sunshine Provision, commonly known in the life sciences industry as the Sunshine Act.

The Sunshine Act, part of sweeping healthcare reform in the United States, details a host of new regulations whereby life sciences companies must provide detailed tracking and reporting to the American public payments made to medical professionals by their commercial and medical affairs divisions.

For the survey, the MSL Society and the Rutgers fellowship program were interested in finding the emerging implications for Medical Science Liaisons as they go about their work in the U. S. pharmaceutical industry.  The purpose of the research was to determine the type and level of impact that the Sunshine act is having and will have on MSL interactions with Key Opinion Leaders (KOLs) and other healthcare providers.

As the study shows, Medical Science Liaisons can provide keen insights on this element of healthcare reform, as they play critical and central roles to industry’s ongoing relationship development with leaders in the medical community. The Rutgers Pharmaceutical Industry Fellowship Program and the MSL Society are pleased with the response generated from the American MSL community, with a total of 167 MSLs representing 40 companies participating in the study.

Some of the early insights include the fact that 73 percent of MSLs report that their companies have instituted standardized reporting systems for tracking payments to physicians and academic institutes, while half of respondents said that their companies are formalizing their training around the Sunshine Act’s requirements.

We have compiled the survey results, along with particular insights gleaned from the MSLs’ responses, in a 15-page report.  Fresh off the presses, members of the MSL Society can find the report in the resources section of the society’s website at www.themsls.org/whitepapers.

The MSL Society invites its members to discuss the report and its findings at our LinkedIn group, Medical Science Liaison and Medical Affairs Networkers.

May
01

The Sunshine Act’s Impact on MSLs Interactions with KOLs

A recent survey conducted by the MSL Society and the Rutgers Institute for Pharmaceutical Industry Fellowships reveals key insights into how MSLs view their role in this new Sunshine Act environment.

As the industry prepares for the implementation of the new Physician Payment Sunshine Act (PPSA), which was passed under the Patient Protection and Affordable Care Act in 2010, the final regulations were published by the Centers for Medicare and Medicaid Services (CMS) in the Federal Register on February 1, 2013. The new rule requires manufacturers of drugs, devices, biologics and medical supplies covered by Medicare, Medicaid or the Children’s Health Insurance Program to report certain payments or other transfers of value made to physicians and teaching hospitals.

Over the last few years there has been a lot of discussion regarding how the new regulation will impact Medical Science Liaisons (MSLs) engagement with Key Opinion Leaders (KOLs) and other healthcare providers. To shed light on this question, the MSL Society recently partnered with the Rutgers Institute for Pharmaceutical Industry Fellowships to design and conduct a survey of current MSLs in the U.S. This survey collected responses from 167 MSLs, representing a variety of companies and therapeutic areas, who provided insights into how MSLs view these regulations and the impact they may have in the field.

According to the survey, most companies are already preparing for the new regulations. In fact, 73% of MSLs surveyed indicated that their companies have already implemented a standardized reporting system for tracking payment requirements to physicians and academic institutes. Even for those that do not have a formal tracking system in place, 11% of respondents indicated that their companies currently have plans to develop a tracking system. In addition, 50% of the MSLs surveyed reported that their company is also offering a formal training program on the new regulations.

The survey also provided insights into how MSLs perceive the level of awareness of these regulations by physicians. Although most MSLs reported that they believed physicians are aware of the general provisions, the level of awareness varied widely. However, MSLs also noted that the physicians with the most comprehensive understanding of the regulations are concerned about how general information may give the public the wrong perception of the relationship between physicians and pharmaceutical companies.

Although the majority of MSLs from the survey do not believe the act will have a negative impact on their relationship with physicians, some did express concerns that the regulations could reduce the frequency and quality of their interactions. Interestingly, a small percentage of MSLs indicated that the new regulations could actually increase the number and quality of interactions. However, most MSLs do agree that the regulations will likely negatively impact sales as access to physicians becomes increasingly restricted.

In addition to the Sunshine Act in the U.S., there are a number of global regulatory changes that will be implemented over the next several years that will result in increased scrutiny between physicians and the pharmaceutical industry. Clearly these regulations will have an effect on how pharmaceutical companies engage with physicians and other healthcare providers. However, the Sunshine Act and other regulatory changes are unlikely to have a negative impact on the relationship that MSLs have with physicians. In fact, MSLs may actually increase the number and quality of interactions they have with physicians as a result of these new regulations.